Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer
Status:
Unknown status
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
Non-small-cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor
(EGFR) mutations are exquisitely sensitive to epidermal growth factor receptor tyrosine
kinase inhibitors (EGFR-TKIs) which is widely used in advanced patients. Whether treatment
with EGFR-TKIs improves outcomes in patients with resected NSCLC harboring EGFR mutations is
still under investigated. This study aims to observe and compare the efficacy and safety of
intercalated combination of chemotherapy plus icotinib in patients undergoing resection of
EGRF mutation-positive non-small cell lung cancer stagingⅠB (with high risk factor) to ⅢA.